Details:

Alternative Title:
J Burn Care Res
Personal Author:
Guillory, Ashley N. ; Herndon, David N. ; Silva, Michael B. ; Andersen, Clark R. ; Suman, Oscar E. ; ... More +
Guillory, Ashley N. ; Herndon, David N. ; Silva, Michael B. ; Andersen, Clark R. ; Suman, Oscar E. ; Finnerty, Celeste C. Less -
Description:
The systemic impact of severe burn injury results in a variety of disorders that require therapeutic intervention. Propranolol, a nonselective β1, β2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines. Oxandrolone, a testosterone mimetic, promotes protein synthesis and anabolism to counter muscle wasting. Coadministration of these drugs is expected to synergistically improve patient outcomes. Testosterone administration is known to alter β-adrenergic receptor-mediated signaling. Here, we determined whether the coadministration of oxandrolone alters plasma propranolol concentrations. Ninety-two pediatric patients with burns covering ≥30% of the TBSA were enrolled in this institutional review board-approved study and randomized to receive propranolol (n = 49) or oxandrolone + propranolol (n = 43). Plasma propranolol concentrations were determined following two dosing strategies: Q6 (liquid formulation; n = 86) and Q24 (extended-release capsule; n = 22). Samples were drawn before drug administration and at regular intervals throughout the next two dosing periods. Heart rate and blood pressure were recorded throughout the study. Propranolol half-life was 3.3 hours for the Q6 drug dosing frequency (P < .0001) and 11.2 hours for the Q24 strategy (P < .0001). Percentage of predicted heart rate declined by 2.8% for each doubling of the propranolol concentration in the Q6 dosing schedule (P < .0001). Percentage of predicted heart rate declined by 2.5% for each doubling of propranolol concentration on the Q24 dosing schedule (P < .0001). Maximum and minimum propranolol plasma concentrations were similar with either dosing regimen. The addition of oxandrolone did not affect any of the measured parameters. Oxandrolone coadministration does not alter propranolol's plasma concentration, half-life, or effect on heart rate. This study is registered at clincialtrials.gov: NCT00675714.
Subject:
[+]
Original Articles
Source:
J Burn Care Res. 2017; 38(4):243-250.
Pubmed ID:
28240622
Pubmed Central ID:
PMC5507814
Document Type:
Journal Article
Funding:
R01 HD049471/HD/NICHD NIH HHS/United States ; R01 GM112936/GM/NIGMS NIH HHS/United States ; U48 DP000043/DP/NCCDPHP CDC HHS/United States ; R01 GM056687/GM/NIGMS NIH HHS/United States ; P50 GM060338/GM/NIGMS NIH HHS/United States ; ... More +
R01 HD049471/HD/NICHD NIH HHS/United States ; R01 GM112936/GM/NIGMS NIH HHS/United States ; U48 DP000043/DP/NCCDPHP CDC HHS/United States ; R01 GM056687/GM/NIGMS NIH HHS/United States ; P50 GM060338/GM/NIGMS NIH HHS/United States ; T32 GM008256/GM/NIGMS NIH HHS/United States ; UL1 RR029876/RR/NCRR NIH HHS/United States Less -
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:9b97633806e341503b59e96de81cb6122a4d7f5d05b3a9f8f1afa80ac5c2124e
Download URL:
https://stacks.cdc.gov/view/cdc/49131/cdc_49131_DS1.pdf
File Type:

Supporting Files

• 	bcr-38-243-g005.gif	gif
  	bcr-38-243-g005.jpg	jpeg
  	bcr-38-243-g006.gif	gif
  	bcr-38-243-g006.jpg	jpeg
  	bcr-38-243-g007.gif	gif
  	bcr-38-243-g007.jpg	jpeg
  	bcr-38-243.nxml	xml
  	bcr-38-243-g001.gif	gif
  	bcr-38-243-g001.jpg	jpeg
  	bcr-38-243-g002.gif	gif
  	bcr-38-243-g002.jpg	jpeg
  	bcr-38-243-g003.gif	gif
  	bcr-38-243-g003.jpg	jpeg
  	bcr-38-243-g004.gif	gif
  	bcr-38-243-g004.jpg	jpeg

More +